Bristol Myers Squibb is proving its worth as an M&A competitor, coming out on top not once but twice in terms of fresh acquisitions. Most recently, the pharma’s $4.1 billion bid for radiopharmaceuticals biotech RayzeBio was enough to beat out two other companies that also put down offers.

The European Medicines Agency (EMA) has swatted away Minoryx Therapeutics’ attempt to bring a rare disease drug candidate to market on the strength of a clinical trial that missed its primary endpoint. But, undeterred, Minoryx and partner Neuraxpharm are seeking a re-examination of the regulatory rejection.

Silo Therapeutics’ ketamine-based drug for Alzheimer’s dementia is effective at alleviating some of the condition’s psychological and behavioral symptoms in mice, according to the company. 

Apnimed is bringing on Pfizer's head of migraine market to be chief commercial officer. Lilly's EVP of global quality is set to retire after 34 years. Cerevel's head of commercial joins Neumora following AbbVie sale.

While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap.

The combination of Merck's Keytruda and Pfizer and Astellas' Padcev recently made waves in bladder cancer—and the broader oncology world—by delivering a massive life-extension benefit. Now, Merck can claim another positive readout for Keytruda in bladder cancer, although this one is short of a home run.

The violations were outlined in U.S. Department of Transportation documents obtained in a records request by the Physicians Committee of Responsible Medicine—an animal research advocacy group that has previously claimed that Neuralink mistreats its animal subjects, in accusations that Neuralink has denied.